Status:
COMPLETED
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
Lead Sponsor:
University of Washington
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Kidney Failure, Chronic
Diabetic Nephropathies
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just completed an 8 month ...
Detailed Description
BACKGROUND: Patients who have been exposed to human tissue by prior transplants, blood transfusion or pregnancy may develop and maintain anti-bodies against these foreign human cells (SENSITIZATION). ...
Eligibility Criteria
Inclusion
- Age range 18 - 75, inclusive
- Able and willing to give written informed consent and comply with the requirements of the study protocol
- Outpatient status
- Patients with a Panel of Reactive Antibodies (PRA) over 10% after an 8-month trial of MMF monotherapy
- Patients with updated immunizations for tetanus, influenza, hepatitis B, pneumococcus
- Patients with a negative purified protein derivative(PPD ) screen for tuberculosis (TB)within the last 6 months. If subject has a prior history of TB or positive PPD, documentation of adequate treatment is required.
- Women who are of childbearing potential must have a negative serum pregnancy test prior to being enrolled in the study and agree to use a medically acceptable method of contraception throughout the study and for twelve months (1 year) after completion of treatment.
- Men must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of treatment.
- Liver enzymes ALT and AST less than 2 times the normal limit.
Exclusion
- Active infection
- Receipt of live vaccine within 4 weeks prior to first infusion.
- Previous treatment with rituximab (MabThera® / Rituxan®)
- History of multiple recurrent infections defined as more than 3 urinary tract infections, 2 episodes of pneumonia or 3 episodes of otitis/sinusitis in one year, or more than two dialysis line or peritoneal infections within one year.
- Infection with hepatitis C virus (HCV) or hepatitis B virus(HBV) or human immunodeficiency virus (HIV), lack of documentation of treatment of a positive PPD, pregnant or breast-feeding, baseline leukopenia, white blood cell count (WBC) less than 4.0, thrombocytopenia (platelet count less than 100,000/mm) or difficult to treat anemia, a hematocrit chronically less than 32 on intravenous iron and EPO (erythropoietin) therapy, history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.
- Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- History of psychiatric disorder
- Significant cardiac or pulmonary disease (including obstructive pulmonary disease)
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00446251
Start Date
December 1 2006
End Date
December 1 2008
Last Update
April 6 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.